Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;20(10):3324-3329.
doi: 10.1111/jocd.14209. Epub 2021 May 25.

Intradermal tranexamic acid microinjections: a novel treatment option for erythematotelangiectatic rosacea

Najla Daadaa  1 , Noureddine Litaiem  1 , Manel Karray  1 , Takwa Bacha  1 , Meriem Jones  1 , Colandane Belajouza Noueiri  2 , Samia Goucha  1 , Faten Zeglaoui  1
Affiliations

Intradermal tranexamic acid microinjections: a novel treatment option for erythematotelangiectatic rosacea

Najla Daadaa et al. J Cosmet Dermatol. 2021 Oct.

Abstract

Background: Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR.

Aims: To evaluate the efficacy and safety of intradermal microinjections of TXA for ETR.

Patients/methods: This was a retrospective study enrolling patients, treated with TXA intradermal microinjections for ETR, from January 2019 to February 2020. Response to treatment was assessed based on subjective symptoms, clinical photographs, and the Investigator Global Assessment of Rosacea Severity Score (IGA-RSS).

Results: Six patients were included. The mean number of monthly intradermal TXA microinjections was 5.1 ± 1.3. The mean decrease of IGA-RSS was 2.4 ± 0.5. Local side effects, mainly transient erythema and swelling, were noticed in three cases. No systemic effects were noted. Clinical improvement, in respondent patients, lasted after 3 months of follow-up.

Conclusion: Intradermal TXA microinjections are a safe and effective treatment option for ETR. The optimal number of monthly sessions has yet to be determined.

Keywords: erythematotelangiectatic rosacea; melasma; mesotherapy; rosacea; tranexamic acid.

PubMed Disclaimer

References

    1. Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148-155.
    1. Joseph Fowler JR. New Agents for the treatment of erythematotelangiectatic rosacea. Cutis. 2014;94(1):6-7.
    1. Cribier B. Rosacea: New data for better care. Ann Dermatol Venereol. 2017;144(8):508-517.
    1. Bharti J, Sonthalia S, Jakhar D. Mesotherapy with Botulinum toxin for the treatment of refractory vascular and papulopustular rosacea. J Am Acad Dermatol. 2018;S0190-9622(18):30808-30809.
    1. Kim MS, Chang SE, Haw S, Bak H, Kim YJ, Lee MW. Tranexamic acid solution soaking is an excellent approach for rosacea patients: a preliminary observation in six patients. J Dermatol. 2013;40(1):70-71.

LinkOut - more resources